**DAC Meeting / 藥物建議委員會 / 药物建议委员会**

**List of references / 參考文獻 / 参考文献**

**Jan 2022 / 2022 年 1 月**

|  | **Generic name**  **藥物學名**  **药物学名** | **Brand name**  **商品名稱**  **商品名称** | **List of references**  **參考文獻 (只備英文版)**  **参考文献 (只备英文版)** |
| --- | --- | --- | --- |
| 1 | Adalimumab | Hyrimoz |  |
| 2 | Alirocumab | Praluent |  |
| 3 | Brentuximab Vedotin | Adcetris |  |
| 4 | Brigatinib | Alunbrig |  |
| 5 | Capmatinib | Tabrecta |  |
| 6 | Dapagliflozin | Forxiga |  |
| 7 | Docetaxel | Taxotere |  |
| 8 | Fentanyl citrate | PecFent |  |
| 9 | Indacaterol / glycopyrronium / mometasone furoate | Enerzair Breezhaler |  |
| 10 | Linaclotide | Linzess |  |
| 11 | Lorlatinib | Lorviqua |  |
| 12 | Lutropin Alfa | Luveris |  |
| 13 | Methoxyflurane | Penthrox |  |
| 14 | Niraparib | Zejula |  |
| 15 | Olaparib | Lynparza |  |
| 16 | Pembrolizumab | Keytruda |  |
| 17 | Riociguat | Adempas |  |
| 18 | Silodosin | Urief |  |
| 19 | Tofacitinib | Xeljanz |  |